This company looks promising with the 3 products they have and with the biotech sector heating up, this one is in my portfolio.

The three poster presentations are entitled:

1) TLN-4601 Inhibits Ras-MAPK Signaling Upstream of MEK;

2) TLN-4601 a Mutated K-Ras Signaling Inhibitor Offers a Therapeutic Option for TK Inhibitors in Resistant Cells with Activating K-Ras Mutations; and

3) M2PK Mediates TLN-232 Cytotoxicity.

The posters will be presented at the AACR Annual Meeting on April 21st from 1:00pm to 5:00pm (local time) at the Colorado Convention Center in Denver. The abstracts are available on Thallion's website at www.thallion.com.

The data from the first TLN-4601 poster provide further evidence that TLN-4601 inhibits the Ras-MAPK pathway and demonstrate that TLN-4601 does not act directly on the MEK or ERK proteins, but instead acts at a unique signaling event to other molecules in development, upstream in the pathway. Ras-MAPK pathway inhibitors represent one of the largest new drug classes that treat cancer patients.

The second TLN-4601 poster indicates that a strong therapeutic opportunity exists for the use of TLN-4601 as a K-Ras inhibitor in combination with tyrosine kinase inhibitors, such as Tarceva(R) or Iressa(R). The results demonstrate the potential for the use of TLN-4601 with these commercially successful EGFr targeting agents for increased potency as well as overcoming resistance to these compounds.

The TLN-232 poster demonstrates that the molecule not only induces cell death, but that the presence of M2PK contributes to its cytotoxicity. M2PK is a validated cancer target that is over-expressed in many tumor types and appears to play a critical role in tumor formation and metabolism. These data suggest that agents targeting M2PK, like TLN-232, would have a broad therapeutic potential.

Thallion is currently enrolling patients in two Phase II clinical trials: a trial evaluating TLN-4601 as a monotherapy treatment for glioblastoma multiforme (an advanced form of brain tumor) patients; and a trial evaluating TLN-232 as a treatment for metastatic melanoma in patients who have failed one prior therapy. The Company expects to report tumor imaging data and initial interim data from the TLN-4601 trial in the second quarter of 2009 and dose escalation data from the TLN-232 trial in the fourth quarter of 2009.